BR112023024595A2 - Receptores de células t direcionando mutações ras e usos dos mesmos - Google Patents

Receptores de células t direcionando mutações ras e usos dos mesmos

Info

Publication number
BR112023024595A2
BR112023024595A2 BR112023024595A BR112023024595A BR112023024595A2 BR 112023024595 A2 BR112023024595 A2 BR 112023024595A2 BR 112023024595 A BR112023024595 A BR 112023024595A BR 112023024595 A BR112023024595 A BR 112023024595A BR 112023024595 A2 BR112023024595 A2 BR 112023024595A2
Authority
BR
Brazil
Prior art keywords
cell receptors
ras mutations
receptors targeting
targeting ras
ras
Prior art date
Application number
BR112023024595A
Other languages
English (en)
Portuguese (pt)
Inventor
A Klebanoff Christopher
S Chandran Smita
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112023024595A2 publication Critical patent/BR112023024595A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
BR112023024595A 2021-05-25 2022-05-25 Receptores de células t direcionando mutações ras e usos dos mesmos BR112023024595A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192783P 2021-05-25 2021-05-25
PCT/US2022/030814 WO2022251283A1 (en) 2021-05-25 2022-05-25 T cell receptors targeting ras mutations and uses thereof

Publications (1)

Publication Number Publication Date
BR112023024595A2 true BR112023024595A2 (pt) 2024-02-15

Family

ID=84230235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024595A BR112023024595A2 (pt) 2021-05-25 2022-05-25 Receptores de células t direcionando mutações ras e usos dos mesmos

Country Status (11)

Country Link
US (1) US20240091361A1 (https=)
EP (1) EP4347639A4 (https=)
JP (1) JP2024520427A (https=)
KR (1) KR20240013750A (https=)
CN (1) CN117545766A (https=)
AU (1) AU2022283277A1 (https=)
BR (1) BR112023024595A2 (https=)
CA (1) CA3219923A1 (https=)
IL (1) IL308755A (https=)
MX (1) MX2023014073A (https=)
WO (1) WO2022251283A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024039576A2 (en) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
AU2024228388A1 (en) * 2023-02-27 2025-10-02 Adaptive Biotechnologies Corp. Therapeutic t cell receptors targeting kras g12d
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
AU2024339041A1 (en) * 2023-09-05 2026-04-16 Bluesphere Bio, Inc. T cell receptors targeting an npm1 neoantigen
WO2025137468A1 (en) * 2023-12-22 2025-06-26 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
CA3116749A1 (en) * 2018-10-24 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途

Also Published As

Publication number Publication date
EP4347639A1 (en) 2024-04-10
CN117545766A (zh) 2024-02-09
WO2022251283A1 (en) 2022-12-01
AU2022283277A1 (en) 2023-12-14
IL308755A (en) 2024-01-01
EP4347639A4 (en) 2025-08-06
CA3219923A1 (en) 2022-12-01
US20240091361A1 (en) 2024-03-21
MX2023014073A (es) 2024-02-21
JP2024520427A (ja) 2024-05-24
AU2022283277A9 (en) 2024-01-04
KR20240013750A (ko) 2024-01-30

Similar Documents

Publication Publication Date Title
BR112023024595A2 (pt) Receptores de células t direcionando mutações ras e usos dos mesmos
BR112019024674A2 (pt) Inibidores covalentes da kras
ECSP22051701A (es) Anticuerpos anti-cd73 y usos de estos
Voss et al. Fatty acid synthase contributes to restimulation-induced cell death of human CD4 T cells
Rao et al. AMPK-dependent and independent effects of AICAR and compound C on T-cell responses
BR112023022297A2 (pt) Receptores quiméricos que alvejam adgre2 e/ou clec12a e usos dos mesmos
BR112018074922A2 (pt) agonista de receptores de glucocorticoides e seus imunoconjugados
Haskó et al. Adenosine: a potential mediator of immunosuppression in multiple organ failure
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
CR20190524A (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
Figueiró et al. Methotrexate up-regulates ecto-5′-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment
BR112023002150A2 (pt) Anticorpos direcionando egfr e uso dos mesmos
Zhdanov et al. Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum l‐asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes
Kaufmann The human intra-S checkpoint response to UVC-induced DNA damage
BR112022022418A2 (pt) Anticorpos de alvejamento de clec12a e uso dos mesmos
MX2023013001A (es) Compuestos para inhibir o degradar itk, composiciones que comprenden los mismos, metodos para su elaboracion y metodos para su uso.
MX2023013723A (es) Polipeptidos de il-21 y construcciones dirigidas.
Chan et al. Carvacrol and eugenol differentially stimulate intracellular Ca2+ mobilization and mitogen-activated protein kinases in Jurkat T-cells and monocytic THP-1 cells
Lee et al. Marine-derived secondary metabolite, Griseusrazin A, suppresses inflammation through heme oxygenase-1 induction in activated RAW264. 7 macrophages
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer
Du et al. A polysaccharide derived from Lentinus edodes impairs the immunosuppressive function of myeloid-derived suppressor cells via the p38 pathways
Kavitha et al. Differential regulation of MRN (Mre11–Rad50–Nbs1) complex subunits and telomerase activity in cancer cells
WO2022010914A3 (en) Brk peptides and methods of use
Shatrova et al. CD25 expression on the surface of Jurkat cells
PY2424677A (es) Mutantes de acetil-coenzima a carboxilasa

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]